In 2012 UBC CPD received the Royal College Accredited CPD Provider Innovation Award for This Changed My Practice.
Dr. Breay Paty
By Dr. Breay Paty on February 18, 2015
Nausea can be a common side effect of GLP-1 receptor agonist, which can sometimes be dose limiting. However, this usually improves with time. As a new class of agents, evidence for the long-term safety of incretins is still emerging. Most of the safety questions involve cardiovascular (CV) risk, as well as pancreatitis and pancreatic cancer.
By Dr. Breay Paty on January 23, 2012
These oral agents, administered once daily, augment endogenous GLP-1, resulting in an A1C reduction of 0.5 – 0.9%. Since GLP-1 does not directly stimulate insulin, they have the advantage of not promoting hypoglycemia or weight gain.
By Dr. Breay Paty on June 20, 2011
Recent studies suggest that the relationship between glucose control (A1C) and cardiovascular disease is more complex than we may have realized.
By Dr. Breay Paty on April 15, 2010
Since their introduction, certain contraindications and side effects have been well known, including worsening heart failure, edema (including macular edema) and weight gain.